Imperial College London Featured PhD Programmes
CoSector, University of London Featured PhD Programmes
Heriot-Watt University Featured PhD Programmes
University of Kent Featured PhD Programmes
University College London Featured PhD Programmes

Inflammation in the tumour microenvironment

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  • Full or part time
    Dr E Parkes
    Dr J Rehwinkel
  • Application Deadline
    No more applications being accepted
  • Competition Funded PhD Project (Students Worldwide)
    Competition Funded PhD Project (Students Worldwide)

Project Description

THE PROJECT
A key part of tackling cancer is understanding the tumour microenvironment, in particular the immune microenvironment. Cancers can gain a survival advantage by encouraging an inflammatory tumour microenvironment, which promotes tumour proliferation and invasion, leading to poor outcomes for patients with cancer.

The cGAS-STING pathway is crucial in cancer inflammation. Recently, new regulators of the cGAS-STING pathway were discovered which affect levels of 2’3’cGAMP (the STING agonist produced by cGAS) in the tumour microenvironment. Inhibitors of these are now being developed for clinical trials. However, it is not currently known how or where these novel cGAMP regulators are produced within the tumour microenvironment. Early data suggests that DNA damage is an important piece of this puzzle, and this project will aim to study this pathway in depth by:

(1) Using DNA damaging agents, radiotherapy and cancer models with DNA repair defects to study the relationship between DNA damage and production of cGAMP regulators. Co-culture using immune cells, overexpression and inhibition of cGAMP regulation will determine the impact on tumour and immune cell behaviour.

(2) Understanding where cGAMP regulators are produced in the tumour microenvironment. Using in vivo models of solid tumours treated with radiotherapy including those lacking DNA repair, single cell analysis will identify cells in the tumour microenvironment that are primarily responsible for regulating cGAMP and STING activation.

(3) Using organoids and co-culture approaches to identify combination therapies where blocking cGAMP regulators alongside giving other immune-targeting treatments (such as viral approaches) could result in improved responses. These approaches will be studied in vivo and could be promising anti-cancer treatment strategies.

This project offers an opportunity for the student to study a key immune pathway working with experts in cGAS-STING signalling, with potential for translation to the clinical setting.

THE TRAINING
Students will partake in a comprehensive induction programme and structured lecture series. Hands-on support is provided on a daily basis by an assigned scientist within the Parkes group. The supervisory team bring combined expertise in molecular biology and DNA repair, STING pathway, innate immune signalling and in vivo modelling. A number of unique tumour models are available for this study, and molecular biology techniques including CRISPR-cas9, site-directed mutagenesis and immunoprecipitation will be familiar to the student at the completion of this project. Expertise in immune signalling and in vivo study will provide the student with the research experience required for a future career in tumour immunology. Access to transcriptomic datasets from solid tumours is available, and the student will be able to attend a comprehensive bioinformatics introductory course, providing them with the tools required for data analysis. The student will be encouraged to develop their own ideas around the work.

PUBLICATIONS
Parkes EE, Walker SM, Taggart LE, McCabe N, Knight L, McCloskey KD, Buckley NE, Savage KI, Salto-Tellez M, McQuaid S, Harte MT, Mullan PB, Harkin DP, Kennedy RD. Activation of STING-dependent innate immune signalling by S-phase specific DNA damage in breast cancer. Journal of the National Cancer Institute 2017; 109(1).

Bridgeman A, Maelfait J, Davenne T, Partidge T, Peng Y, Mayer A, Dong T, Kaever V, Borrow P, Rehwinkel J. Viruses transfer the antiviral second messenger cGAMP between cells. Science 2015; 349(6253):1228-32

Funding Notes

All complete applications received by 12 noon (UK time) on Friday 10 January 2020 will automatically be considered for all relevant competitive University and funding opportunities, including the Clarendon Fund, Medical Research Council funding, and various College funds. Please refer to the Funding and Costs webpage (https://www.ox.ac.uk/admissions/graduate/courses/dphil-oncology) for this course for further details relating to funded scholarships and divisional funding opportunities.

Funded studentships are highly competitive and are awarded to the highest ranked applicant(s) based on the advertised entry requirements for each programme of study.

References

Whilst you must register three referees, the department may start the assessment of your application if two of the three references are submitted by the course deadline and your application is otherwise complete. Please note that you may still be required to ensure your third referee supplies a reference for consideration.

Academic references are strongly encouraged, though you may use up to one professional reference provided that it is relevant to the course.

How good is research at University of Oxford in Clinical Medicine?

FTE Category A staff submitted: 238.51

Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities


FindAPhD. Copyright 2005-2020
All rights reserved.